Drugs Affecting Blood and Blood Formation
>>>Part 2
41.1 Absorption of oral iron preparations can be facilitated
by coadministering:
A. Antacids
B. Tetracyclines
C. Phosphates
D. Ascorbic acid
41.2 The gut controls the entry of ingested iron in the body by:
A. Regulating the availability of apoferritin
which acts as the carrier of iron across the mucosal cell
B. Regulating the turnover of apoferritin-ferritin
interconversion in the mucosal cell
C. Complexing excess iron to form ferritin which
remains stored in the mucosal cell and is shed off
D. Regulating the number of transferrin receptors
on the mucosal cell
41.3 In the iron deficient state, transferrin receptors increase in number on the:
A. Intestinal mucosal cells
B. Erythropoietic cells
C. Reticuloendothelial cells
D. All of the above
41.4 The percentage of elemental iron in hydrated ferrous sulfate is:
A. 5%
B. 10%
C. 20%
D. 33%
41.5 Select the oral iron preparation which does not impart
metallic taste and has good oral tolerability despite
high iron content but whose efficacy in treating iron
deficiency anaemia has been questioned:
A. Iron hydroxy polymaltose
B. Ferrous succinate
C. Ferrous fumarate
D. Ferrous gluconate
41.6 The daily dose of elemental iron for maximal haemopoietic
response in an anaemic adult is:
A. 30 mg
B. 100 mg
C. 200 mg
D. 500 mg
41.7 The side effect which primarily limits acceptability of
oral iron therapy is:
A. Epigastric pain and bowel upset
B. Black stools
C. Staining of teeth
D. Metallic taste
41.8 Choose the correct statement about severity of side
effects to oral iron medication:
A. Ferrous salts are better tolerated than ferric salts
B. Complex organic salts of iron are better
tolerated than inorganic salts
C. Liquid preparations of iron are better
tolerated than tablets
D. Tolerability depends on the quantity of elemental
iron in the medication
41.9 The following is not a valid indication for parenteral iron therapy:
A. Inadequate response to oral iron due to
patient noncompliance
B. Anaemia during pregnancy
C. Severe anaemia associated with chronic bleeding
D. Anaemia in a patient of active rheumatoid arthritis
41.10 Iron sorbitol-citric acid differs from iron dextran in that:
A. It cannot be injected i.v.
B. It is not excreted in urine
C. It is not bound to transferrin in plasma
D. It produces fewer side effects
41.11 Choose the correct statement about iron therapy:
A. Haemoglobin response to intramuscular iron
is faster than with oral iron therapy
B. Iron must be given orally except in pernicious anaemia
C. Prophylactic iron therapy must be given during pregnancy
D. Infants on breastfeeding do not require medicinal iron
41.12 A patient of iron deficiency anaemia has been put on
iron therapy. What should be the rate of rise in
haemoglobin level of blood so that response is considered
adequate:
A. 0.05 – 0.1 g% per week
B. 0.1 – 0.2 g% per week
C. 0.5 – 1.0 g% per week
D. More than 1.0 g% per week
41.13 The following chelating agent should not be used
systemically to treat acute iron poisoning in a child:
A. Desferrioxamine
B. Calcium edetate
C. Dimercaprol
D. Calcium disodium diethylene triamine penta acetic acid
41.14 Megaloblastic anaemia occurs in:
A. Vitamin B12 but not folic acid deficiency
B. Folic acid but not Vitamin B12 deficiency
C. Either Vitamin B12 or folic acid deficiency
D. Only combined Vitamin B12 + folic acid
deficiency
41.15 The metabolic reaction requiring vitamin B12 but not folate is:
A. Conversion of malonic acid to succinic acid
B. Conversion of homocysteine to methionine
C. Conversion of serine to glycine
D. Thymidylate synthesis
41.16 The daily dietary requirement of vit B12 by an adult is:
A. 1-3 μg
B. 50-100 μg
C. 0.1-0.5 mg
D. 1-3 mg
41.17 The following factor(s) is/are required for the absorption of dietary vitamin B12:
A. Gastric acid
B. Gastric intrinsic factor
C. Transcobalamine
D. Both ‘A’ and ‘B’
41.18 A 60-year-old patient presented with anorexia, weakness,
paresthesia and mental changes. His tongue
was red, tendon reflexes were diminished, haemoglobin
was 6 g% with large red cells and neutrophils
had hypersegmented nuclei. Endoscopy revealed
atrophic gastritis. Deficiency of which factor is likely
to be responsible for his condition:
A. Folic acid
B. Vitamin B12
C. Pyridoxine
D. Riboflavin
41.19 Features of methylcobalamin include the following:
A. It is an active coenzyme form of vit B12
B. It is required for the synthesis of S-adenosyl methionine
C. It is specifically indicated for correcting
neurological defects of vit B12 deficiency
D. All of the above
41.20 Hydroxocobalamin differs from cyanocobalamin in that:
A. It is more protein bound and better retained
B. It is beneficial in tobacco amblyopia
C. It benefits haematological but not neurological
manifestations of vit B12 deficiency
D. Both ‘A’ and ‘B’ are correct
41.21 Megaloblastic anaemia developing under the following
condition is due entirely to folate deficiency not
associated with vitamin B12 deficiency:
A. Malnutrition
B. Blind loop syndrome
C. Phenytoin therapy
D. Pregnancy
41.22 A patient of megaloblastic anaemia was treated with
oral folic acid 5 mg daily. After 2 weeks he reported
back with cognitive deficit, sensory disturbance,
depressed knee jerk, while blood picture and haemoglobin
level were improved. What could be the most
likely explanation:
A. Folic acid was not adequately absorbed resulting in partial response
B. Folate therapy has precipitated vitamin B12 deficiency in the neural tissue
C. Folate therapy has unmasked pyridoxine deficiency
D. Patient has folate reductase abnormality in the nervous system
41.23 Folinic acid is specifically indicated for:
A. Prophylaxis of neural tube defect in the offspring of women receiving anticonvulsant
medication
B. Counteracting toxicity of high dose methotrexate
C. Pernicious anaemia
D. Anaemia associated with renal failure
41.24 Recombinant human erythropoietin is indicated for:
A. Megaloblastic anaemia
B. Haemolytic anaemia
C. Anaemia in patients of thalassemia
D. Anaemia in chronic renal failure patients
41.25 A patient of chronic renal failure maintained on
intermittent haemodialysis has anaemia not responding
to iron therapy. Which of the following additional drug is indicated:
A. Epoetin
B. Cyanocobalamin
C. Folic acid
D. Pyridoxine
Ans:
41.1D 41.2 C 41.3 B 41.4 C 41.5 A 41.6 C 41.7 A 41.8D 41.9 B 41.10 A 41.11 C 41.12 C 41.13 C 41.14 C 41.15 A 41.16 A 41.17D 41.18 B 41.19D 41.20D 41.21 C 41.22D 41.23 B 41.24D 41.25 A
Thank you for sharing knowledge
ReplyDeleteE-pharmacy market in India